Intellia Therapeutics to Present at March Investor Healthcare Conferences

Print
| Source: Intellia Therapeutics, Inc.

CAMBRIDGE, Mass., March 01, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that company senior leaders will present at key March investor healthcare conferences, including the Cowen and Company 37th Annual Health Care Conference, the Goldman Sachs Third Annual Innovation Symposium, and the Oppenheimer 27th Annual Healthcare Conference.

Details of the upcoming presentations are as follows:

Wednesday, March 8th
Cowen and Company 37th Annual Health Care Conference
Who: Nessan Bermingham, Ph.D., chief executive officer & founder
Location: Boston, Massachusetts
Presentation Time: 8:40 am ET

Wednesday, March 15th
The Goldman Sachs Third Annual Innovation Symposium
Gene Editing and CRISPR Panel
Who: Nessan Bermingham, Ph.D., chief executive officer & founder
Location: New York, New York
Panel Time: 10:15 am ET

Wednesday, March 22nd
The Oppenheimer 27th Annual Healthcare Conference
Who: John Leonard, M.D., executive vice president, R&D
Location: New York, New York
Presentation Time: 2:45 pm ET

Individuals may access the presentations for available conferences via live webcast on the Intellia website at www.intelliatx.com under "Events & Presentations" in the "Investor Relations" section. When available, replays of these webcasts will be available on the site for 90 days following the live events.

About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.

Media Contact:
Jennifer Mound Smoter 
Senior Vice President, External Affairs & Communications
+1 (857) 706-1071
jenn.smoter@intelliatx.com

Investor Contact:
Graeme Bell
Chief Financial Officer
+1 (857) 706-1081 
graeme.bell@intelliatx.com